Oncolix
Houston · Founded 2007
About Oncolix
Oncolix is a clinical-stage biotechnology company that is focused on cancer. The company is currently conducting a Phase I clinical trial for the indication of ovarian cancer. The drug, Prolanta, is a prolactin receptor antagonist. The mechanism of action is autophagocytosis or autophagy.
Company Facts
- Founded: 2007
- Legal name: Oncolix Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $8.5M
- Last round: Series Unknown (Jan 2015)
- Website: oncolixbio.com
- Phone: 9182533295
Social Profiles
Canonical: https://fsome.com/organization/oncolix-8344602 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.